Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: A controlled comparison

Psycho-Oncology

Volumn 24, Issue 4, 2015, Pages 472-477

  Lee, Morgan ^a   Jim, Heather S ^b   Fishman, Mayer ^b   Zachariah, Babu ^c   Heysek, Randy ^b   Biagioli, Matthew ^b   Jacobsen, Paul B ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

androgen deprivation therapy; depression; oncology; prostate cancer; quality of life

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER PATIENT; CANCER SURGERY; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DEPRESSIVE SYMPTOMATOLOGY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; SHORT PORTABLE MENTAL STATUS QUESTIONNAIRE; SYMPTOMATOLOGY; ADJUVANT CHEMOTHERAPY; CASE CONTROL STUDY; DEPRESSIVE DISORDER; LONGITUDINAL STUDY; MIDDLE AGED; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; PSYCHOLOGY; RISK FACTOR; VERY ELDERLY;

ANTIANDROGEN; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GOSERELIN; LEUPRORELIN;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; DEPRESSION; DEPRESSIVE DISORDER; GOSERELIN; HUMANS; LEUPROLIDE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84926674511     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.3608     Document Type: Article

References (30)

1. Howlader N, Noone A, Krapcho M, et al., SEER cancer statistics review, 1975-2009 (vintage 2009 populations). National Cancer Institute. Bethesda, MD, 2012. based on November 2011 SEER data submission, posted to the SEER web site, April 2012. Available from URL: http://seer.cancer.gov/csr/1975-2009-pops09/ [accessed July 26, 2013].
2. Loblaw DA, Virgo KS, Nam R, et al., Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-1605.
3. Barrass BJR, Thurairaja R, Persad RA,. More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer. BJU Int 2004; 93: 1175-1176.
4. Shahinian VB, Kuo Y-f, Freeman JL, Orihuela E, Goodwin JS,. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-1624.
5. Smith MR,. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007; 14: 247-254.
6. Chen A, Petrylak D,. Complications of androgen deprivation therapy in men with prostate cancer. Curr Oncol Rep 2004; 6: 209-215.
7. Taylor LG, Canfield SE, Du XL,. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009; 115: 2388-2399.
8. Casey RG, Corcoran NM, Goldenberg SL,. Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl 2012; 14: 226-231.
9. Amore M, Innamorati M, Costi S, Sher L, Girardi P, Pompili M,. Partial androgen deficiency, depression, and testosterone supplementation in aging men. Int J Endocrinol 2012; 2012: Article ID 280724. doi: 10.1155/2012/280724
10. Rosenblatt DE, Mellow A,. Depression during hormonal treatment of prostate cancer. J Am Board Fam Pract 1995; 8: 317-320.
11. Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN,. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004; 29: 1071-1081.
12. Cherrier MM, Aubin S, Higano CS,. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psycho-Oncology 2009; 18: 237-247.
13. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006; 166: 465-471.
14. Soyupek F, Soyupek S, Perk H, Özorak A,. Androgen deprivation therapy for prostate cancer: effects on hand function. Urol Oncol 2008; 26: 141-146.
15. DiBlasio CJ, Hammett J, Malcolm JB, et al., Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. Can J Urol 2008; 15: 4249-4256.
16. Pirl WF, Greer JA, Goode M, Smith MR,. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho-Oncology 2008; 17: 148-153.
17. Pirl WF, Siegel GI, Goode MJ, Smith MR,. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psycho-Oncology 2002; 11: 518-523.
18. Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M,. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 2004; 10: 7575-7582.
19. Stone P, Hardy J, Huddart R, A'Hern R, Richards M,. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36: 1134-1141.
20. Hervouet S, Savard J, Ivers H, Savard MH,. Depression and androgen deprivation therapy for prostate cancer: a prospective controlled study. [published online ahead of print March 11 2013 ]. Health Psychol 2013. doi: 10.1037/a0031639
21. Timilshina N, Breunis H, Alibhai S,. Impact of androgen deprivation therapy on depressive symptoms in men with nonmetastatic prostate cancer. Cancer 2012; 118: 1940-1945.
22. Radloff LS,. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
23. Weissman MM, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ,. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 1977; 106: 203-214.
24. Beeber LS, Shea J, McCorkle R,. The Center for Epidemiological Studies Depression Scale as a measure of depressive symptoms in newly diagnosed patients. J Psychosoc Oncol 1998; 16: 1-20.
25. Hann D, Winter K, Jacobsen P,. Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res 1999; 46: 437-443.
26. Steer RA, Ball R, Ranieri WF, Beck AT,. Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients. J Clin Psychol 1999; 55: 117-128.
27. Sheikh JI, Yesavage JA, Brooks JO, et al., Proposed factor structure of the Geriatric Depression Scale. Int Psychogeriatr 1991; 3: 23-28.
28. Aragon-Ching JB, Williams KM, Gulley JL,. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007; 12: 4957-4971.
29. Vedhara K, Irwin M,. Human Psychoneuroimmunology. Oxford University Press: New York, NY, 2005.
30. Bennett G, Badger TA., Depression in men with prostate cancer. Oncol Nurs Forum 2005; 32: 545-556.